The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement. Using HEK293, it has been demonstrated that addition of recombinant human insulin to commercially available chemically defined media can be used as a supplement to increase VCD and specific viral yield.
If you want to know more you can read the application study, which National Research Council Canada has created in collaboration with Novo Nordisk Pharmatech A/S here.